Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
TRML Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.12 - $48.31
Previous CloseN/A
Volume43.44K
Average Volume (3M)311.89K
Market Cap
$317.20M
Enterprise Value$380.84M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 25, 2025EPS Estimate
-0.87Last Dividend Ex-Date
Oct 20, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding25,642,610
10 Day Avg. Volume369,991
30 Day Avg. Volume311,889
Standard Deviation0.27
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.54K
Enterprise Value/Ebitda-5.36
Forecast
1Y Price Target
$55.40Price Target Upside347.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Tourmaline Bio News
PremiumCompany Announcements
Tourmaline Bio Updates on Clinical Progress and Outlook
PremiumCompany Announcements
Tourmaline Bio Unveils Clinical Progress and New Indication
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing Phase 2b trial of pacibekitug in thyroid eye disease is expected to report topline results, which could potentially lead to pacibekitug becoming a first-line therapy for TED.
Financial StabilityTRML reported cash and equivalents of ~$314 million, which management expects will provide cash runway into 2027, indicating financial stability.
Bears Say
Financial PerformanceTRML reported a net loss of $20.2 million or ($0.78) per share in 3Q24, reflecting financial challenges.
---
Ownership Overview
Currently, No data available
---
TRML FAQ
What was Tourmaline Bio’s price range in the past 12 months?
Tourmaline Bio lowest stock price was $12.12 and its highest was $48.31 in the past 12 months.
What is Tourmaline Bio’s market cap?
Tourmaline Bio’s market cap is $317.20M.
When is Tourmaline Bio’s upcoming earnings report date?
Tourmaline Bio’s upcoming earnings report date is Mar 25, 2025 which is in 31 days.
How were Tourmaline Bio’s earnings last quarter?
Tourmaline Bio released its earnings results on Nov 07, 2024. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.817 by $0.037.
Is Tourmaline Bio overvalued?
According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued.
Does Tourmaline Bio pay dividends?
Tourmaline Bio pays a Notavailable dividend of $1.511 which represents an annual dividend yield of N/A. See more information on Tourmaline Bio dividends here
What is Tourmaline Bio’s EPS estimate?
Tourmaline Bio’s EPS estimate is -0.87.
How many shares outstanding does Tourmaline Bio have?
Tourmaline Bio has 25,642,610 shares outstanding.
What happened to Tourmaline Bio’s price movement after its last earnings report?
Tourmaline Bio reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.817. Following the earnings report the stock price went up 0.949%.
Which hedge fund is a major shareholder of Tourmaline Bio?
Currently, no hedge funds are holding shares in TRML
---
Tourmaline Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.40 (347.86% Upside)
$55.40 (347.86% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.33%
12-Months-Change
Fundamentals
Return on Equity
-27.54%
Trailing 12-Months
Asset Growth
117.43%
Trailing 12-Months
Company Description
Tourmaline Bio
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
---
TRML Stock 12 Month Forecast
Average Price Target
$55.40
▲(347.86% Upside)
Technical Analysis
Best Analysts Covering TRML
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-7.92%
assigned a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -7.92% per trade.
---